Enhancing Drug Compliance in Lipid-Lowering Treatment
Judith H. LaRosa, PhD;
John C. LaRosa, MD
Arch Fam Med. 2000;9:1169-1175.
Hyperlipidemia and the atherosclerotic conditions that result from it are well recognized as major contributors to coronary heart disease (CHD). Fortunately, several large-scale clinical trials have shown that there are effective treatments that can substantially lower atherogenic lipid levels and thereby reduce the risk of CHD mortality and morbidity. However, duplication of these dramatic trial results can be negatively affected in "real life" clinical practice by an important issue: compliance. No medications will work if patients do not take them. Unfortunately, patients who need lipid-lowering therapy are likely to need it long-term, perhaps for a lifetime. Yet, many do not adhere to the prescribed medication regimen. This article reviews some major studies of compliance for lipid-lowering drugs. The reasons why patients do not take them as prescribed vary: poor education, lack of understanding, cost, provider indifference, and others. Achieving compliance requires a multifaceted approach. It can be enhanced by encouraging patients to talk openly about their medication habits and by convincing them of the long-term benefits of reaching and maintaining target low-density lipoprotein cholesterol levels. Although more studies focusing on compliance specifically regarding CHD are needed, the current literature does provide some guidance.
From the Departments of Preventive Medicine and Community Health (Dr J. H. LaRosa) and Medicine (Dr J. C. LaRosa), State University of New York Health Science Center at Brooklyn.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Medication Adherence Following Coronary Artery Bypass Graft Surgery: Assessment of Beliefs and Attitudes
Khanderia et al.
The Annals of Pharmacotherapy 2008;42:192-199.
ABSTRACT
| FULL TEXT
Use of pictorial aids in medication instructions: A review of the literature
Katz et al.
Am J Health Syst Pharm 2006;63:2391-2397.
ABSTRACT
| FULL TEXT
Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease
Gemmell et al.
J. Epidemiol. Community Health 2005;59:1041-1046.
ABSTRACT
| FULL TEXT
Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy
Benner et al.
Am J Health Syst Pharm 2005;62:1468-1475.
ABSTRACT
| FULL TEXT
Adherence to Statin Therapy and LDL Cholesterol Goal Attainment by Patients With Diabetes and Dyslipidemia
Parris et al.
Diabetes Care 2005;28:595-599.
ABSTRACT
| FULL TEXT
Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device
Cheng et al.
Am J Health Syst Pharm 2005;62:411-415.
FULL TEXT
Reducing the Risk of Coronary Heart Disease via Lipid Reduction
Spratt
JAOA: Journal of the American Osteopathic Association 2004;104:9S-13S.
ABSTRACT
| FULL TEXT
Benefits of Individualized Counseling by the Pharmacist on the Treatment Outcomes of Hyperlipidemia in Hong Kong
Lee et al.
J Clin Pharmacol 2004;44:632-639.
ABSTRACT
| FULL TEXT
Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study
Wei et al.
Heart 2002;88:229-233.
ABSTRACT
| FULL TEXT
|
